Tiziana Life Sciences Posts Early PET Data Showing Reduced Brain Inflammation in MSA Trial of Intranasal Foralumab
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tiziana Life Sciences ( (TLSA) ) just unveiled an announcement.
On May 14, 2026, Tiziana Life Sciences reported initial PET imaging data from the first two patients with Multiple System Atrophy enrolled in its Phase 2 trial of intranasal foralumab. Quantitative PET analysis showed up to about 35% reductions in standardized uptake value and roughly 24% reductions in standardized uptake value ratio in disease-relevant brain regions, including the basal ganglia and cerebellar white matter, indicating decreased neuroinflammatory activity.
The company noted that MSA currently has no approved disease-modifying treatments and highlighted that this is the third indication, after non-active secondary progressive multiple sclerosis and moderate Alzheimer’s disease, to show marked inflammation reduction on PET scans with intranasal foralumab. Tiziana plans to continue dosing additional MSA patients to validate these early findings, which could strengthen its positioning in neuroinflammation and support the broader potential of its intranasal anti-CD3 platform for high unmet-need neurodegenerative conditions.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on developing immunotherapies using alternative delivery routes, particularly intranasal administration. Its lead asset is intranasal foralumab, a fully human anti-CD3 monoclonal antibody aimed at treating neuroinflammatory and neurodegenerative diseases with potentially improved safety and tolerability over intravenous therapies.
Average Trading Volume: 146,575
Technical Sentiment Signal: Strong Buy
Current Market Cap: $185.4M
For an in-depth examination of TLSA stock, go to TipRanks’ Overview page.
